Table 3.
Patient/cycle characteristics for case–control study
| PGS Group | Control Group | |
|---|---|---|
|
n IVF cycles |
30 |
30 |
|
Age (years) |
38.7 ± 4.0 |
39.2 ± 4.0 |
| Range |
27.1–45.0 |
27.7–45.4 |
|
AMH (ng/mL) |
1.5 ± 1.4 |
1.4 ± 1.8 |
|
Total gonadotropin dosage (IU)2 |
4840 ± 1825 |
5934 ± 2330 |
|
Oocyte yields (n) |
9.7 ± 5.6 |
9.7 ± 5.4 |
| Range |
2–25 |
2–25 |
|
Embryos transferred (n)1 |
1.6 ± 0.8 |
2.9 ± 1.0 |
|
Implantation rate (%)3 |
26.4 |
9.5 |
|
Heartbeats/Embryos transferred |
14/53 |
9/95 |
|
Pregnancy rate (%)4 |
36.4 |
21.2 |
| n |
12/33 |
7/33 |
|
Miscarriage rate (%) |
8.3 |
14.3 |
| n | 1/12 | 1/7 |
1 Controls had significantly more embryo transferred (P < 0.0001), and 2 utilized marginally more total gonadotropins (P = 0.046). 3 The implantation rate was significantly higher in PGS cycles (P = 0.008). 4 In univariate analyses pregnancy rates and miscarriage rates did not differ significantly. After appropriate adjustments, logistic regression analysis demonstrated 4.58-times the odds of clinical pregnancy after PGS than in controls (95% CI 1.102 to 19.060, Exp 4.584; P = 0.036).